INTRODUCTION
============

Living organisms must sense nutrient availability to finely modulate their anabolic and catabolic processes and adjust to various environments. Amino acid availability signals are sensed through multiple mechanisms, including the SPS, GCN2, and target of rapamycin complex 1 (TORC1) pathways ([@B54]; [@B13]; [@B27]). TORC1 is a multisubunit protein kinase complex conserved from yeast to mammals: in the yeast *Saccharomyces cerevisiae*, TORC1 consists of Tor1 or Tor2, Kog1, Lst8, and Tco89, whereas mammalian TORC1 contains mTor, Raptor, mLst8, Deptor, and PRAS40 ([@B28]; [@B43]; [@B38]). By integrating stimuli such as energy level, stress, and hormonal signals in addition to nutrient availability, TORC1 regulates fundamental processes involved in cellular growth, such as translation, ribosomal biogenesis, and autophagy ([@B7]; [@B9]).

TORC1 is regulated by heterodimeric small GTPases, RagA/B--RagC/D in mammals and Gtr1/Gtr2 in budding yeast ([@B14]; [@B44]; [@B5]; [@B18]). When RagA/B and Gtr1 are in their GTP-bound forms, they bind directly to TORC1 ([@B42]; [@B45]). In mammals, this binding recruits mTORC1 to the lysosome surface and allows it to associate with its activator Rheb, another small GTPase ([@B41]). Thus the dynamic relocation of mTORC1 underlies its regulatory mechanism. By contrast, it is not known whether the budding yeast Rheb homologue also serves as a TORC1 activator and, if so, how the activation is achieved ([@B52]). In addition, we observed that relocation of yeast Tor1 from the vacuolar membrane to other sites in response to nitrogen starvation is not as dramatic: under these conditions, the percentage of cells with vacuole-associated Tor1 decreases from 60 to 39% ([@B24]). Therefore it remains unclear how the regulation of yeast TORC1 activity is related to its localization.

The RagA/B/C/D complex is anchored to the lysosomal membrane via a scaffold protein complex called Ragulator ([@B41]), which consists of p18/Lamtor1, p14/Lamtor2, MP1/Lamtor3, C7orf59/Lamtor4, and HBXIP/Lamtor5 ([@B41]; [@B4]). Ragulator also functions as a guanine nucleotide exchange factor for RagA/B and thus plays a key role in the regulation of Rag and mTORC1 activity ([@B4]). The budding yeast counterpart of Ragulator is Ego, which contains at least three molecules: Ego1 and an Ego3 dimer ([@B8]; [@B10]; [@B55]). It remains unknown whether yeast Ego is structurally similar to Ragulator. Here we show that the uncharacterized protein Ycr075w-a is novel subunit of Ego. By characterizing its properties, we show that the Ego/Gtr/Tor1 complex is dynamically relocated according to the nucleotide-bound state of Gtr1 and Gtr2.

RESULTS
=======

Identification of Ego2 as a novel subunit of Ego
------------------------------------------------

Yeast Ego is believed to consist of at least three subunits (one molecule of Ego1 protein and an Ego3 dimer), whereas mammalian Ragulator possesses five subunits ([@B4]). A recent analysis using HHPred software predicted that mammalian C7orf59 and HBXIP have secondary structure organization similar to that of two uncharacterized yeast proteins, Ycr075w-a and Ynr034w-a ([@B26]). Hence we examined the relationship between Ycr075w-a and Ynr034w-a and the other yeast Ego subunits. During the review period after the original submission of our manuscript, [@B39]) reported their characterization of these proteins. On the basis of their findings and the results we describe later, we will refer to Ycr075w-a as Ego2.

C-terminally green fluorescent protein (GFP)--tagged Ego1 localizes on the vacuolar membrane and perivacuolar foci ([Figure 1A](#F1){ref-type="fig"}; [@B5]). This pattern was also observed for Ego2-GFP ([Figure 1A](#F1){ref-type="fig"}). When Ego3 was C-terminally tagged with 3xmCherry fluorescence protein, it colocalized with Ego1-GFP not only on the vacuolar membrane, but also on perivacuolar foci; a similar colocalization was observed for Ego2-GFP ([Figure 1A](#F1){ref-type="fig"}). This pattern of Ego2-GFP localization was completely lost in ∆*ego1* mutant cells, and only faint signals remained on the vacuole in ∆*ego3* ([Figure 1B](#F1){ref-type="fig"}). Similarly, proper localization of Ego3 required both Ego1 and Ego2 ([Figure 1C](#F1){ref-type="fig"}). By contrast, Ego1 localization on vacuolar membrane was maintained even in ∆*ego2* and ∆*ego3* mutants ([Figure 1D](#F1){ref-type="fig"}). Ego1 possesses a possible myristoylation sequence (MGXXXS/T) at the N-terminal SH4 domain ([@B1]). In fact, a glycine-to-alanine point mutation in the sequence resulted in a dramatic loss of vacuolar localization ([Figure 1E](#F1){ref-type="fig"}), indicating that it is directly anchored to the vacuole via its lipid modification. On the basis of these results, we postulate that Ego3 and Ego2 are anchored to the vacuolar membrane via Ego1, and Ego2 and Ego3 stabilize each other's association to Ego1.

![Ego2 is localized on the vacuole and its associated puncta, along with Ego1 and Ego3. (A) Diploid cells expressing both Ego1-GFP and Ego3-3xmCherry (YKY033-A) or Ego2-GFP and Ego3-3xmCherry (YKY037-A). (B--D) WT (SKY331-A), ∆*ego1* (SKY353-A), and ∆*ego3* (SKY354-A) cells expressing Ego2-GFP (B), WT (SKY114-A), ∆*ego1* (SKY115-A), and ∆*ego2* (SKY340-A) cells expressing Ego3-GFP (C), and WT (SKY108-A), ∆*ego3* (SKY326-A), and ∆*ego2* (SKY339-A) cells expressing Ego1-GFP (D) were stained with FM4-64. (E) ∆*ego1* (NKY002) cells expressing Ego1-GFP (WT \[pSK384\] or G2A mutant \[pSK385\]). Bar, 5 μm.](382fig1){#F1}

To determine whether Ego2 is directly associated with Ego1, we performed yeast two-hybrid analysis. Robust positive signals were observed with the combination of either AD or BD vectors ([Figure 2A](#F2){ref-type="fig"}). Furthermore, Ego2-GFP could be pulled down by Ego1--tandem affinity purification (TAP) from lysate of wild-type (WT) yeast but not ∆*ego3* mutant cells ([Figure 2B](#F2){ref-type="fig"}). These observations suggest that Ego2 is directly associated with Ego1 and that Ego3 stabilizes the Ego1--Ego2 interaction. Similarly, we detected robust direct interaction between Ego1 and Ego3, as previously reported (Supplemental Figure S1; [@B55]). Ego3-GFP could be pulled down by Ego1-TAP in WT yeast but not in *ego2* mutant cells ([Figure 2C](#F2){ref-type="fig"}). On the other hand, the two-hybrid interaction between Ego3 and Ego2 was weak and detectable in only one AD/BD combination ([Figure 2A](#F2){ref-type="fig"}). Ego3-GFP could be pulled down by Ego2-TAP, but this interaction was lost in the ∆*ego1* mutant ([Figure 2D](#F2){ref-type="fig"}). Together these findings suggest that the interaction between Ego3 and Ego2 depends on Ego1 and that Ego2 is a novel subunit of Ego.

![Ego2 is associated with Ego1 and Ego3. (A) Yeast two-hybrid analysis to detect interactions between Ego1 and Ego2 or Ego2 and Ego3. Strain PJ69-4A harboring pGAD-C1 and pGBD-C1, empty vectors, and pYKY8, 9, or 11--13 was serially 10-fold diluted and spotted on the indicated selective plates. (B--D) Lysate of cells expressing Ego1-TAP (B), Ego3-TAP (C), or Ego2-TAP (D) were subjected to TAP pull down using immunoglobulin G--Sepharose and Western blotting. Strains used were SKY331-A, SKY256-A, YKY030-A, and SKY469-A (B); SKY256-A, SKY114-A, YKY028-A, and SKY470-A (C); and SKY331-A, YKY024-A, YKY031-A, and YKY131 (D).](382fig2){#F2}

Ego2 mutants are partially defective in TORC1 activation
--------------------------------------------------------

Growth of *ego* mutants was sensitive to the TORC1 inhibitor rapamycin ([Figure 3A](#F3){ref-type="fig"}; [@B5]). The ∆*ego2* mutant also exhibited some growth sensitivity to rapamycin relative to the parental WT strain, although this effect was weaker than in the ∆*gtr1*, ∆*ego1*, and ∆*ego3* mutants ([Figure 3A](#F3){ref-type="fig"}). Gtr1 is kept as a GTP-bound form in the mutant of *NPR2*, a subunit of the SEACIT complex, which has GTPase activation protein (GAP) activity toward Gtr1, leading to persistent activation of TORC1 ([@B3]; [@B36], [@B37]; [@B24]). The ∆*gtr1*∆*npr2*, ∆*ego1*∆*npr2*, and ∆*ego3*∆*npr2* double-deletion mutants exhibited rapamycin sensitivity comparable to that of the single-deletion mutants of ∆*gtr1*, ∆*ego1*, and ∆*ego3*, consistent with lack of Gtr1 function in these mutants ([Figure 3A](#F3){ref-type="fig"}). On the contrary, ∆*ego2*∆*npr2* cells did not show such severe sensitivity, implying that Gtr1 activity somehow remains.

![The ∆*ego2* mutant exhibits a partial defect in Gtr1-dependent TORC1 activation. (A) Wild-type (BY4741), ∆*gtr1* (NKY004), ∆*ego1* (NKY002), ∆*ego3* (NKY003), ∆*ego4* (YKY010), ∆*ego2* (YKY011), ∆*npr2* (SKY032-A), ∆*ego2*∆*ego4* (YKY012-A), ∆*gtr1*∆*npr2* (SKY037-A), ∆*ego1*∆*npr2* (SKY039-A), ∆*ego3*∆*npr2* (SKY040-A), and ∆*ego2*∆*npr2* (SKY498-A) cells were serially 10-fold diluted and spotted onto YPD plates with or without 0.2 μg/ml rapamycin and grown at 30°C for 3 d. The strains were also cultured for 6 h in liquid YPD containing 0.2 μg/ml rapamycin and then grown on YPD plates at 30°C for 3 d. (B) Lysates of cells harboring Sch9-6HA in the WT (SKY116), ∆*gtr1* (SKY118-A), ∆*ego1* (SKY120-A), or ∆*ego2* (SKY467-A) background were treated with NTCB and subjected to Western blotting. (C) Each strain harboring Pho8Δ60 was grown in YPD and nitrogen starved for 4 h. Lysates were subjected to ALP assay to measure autophagic activity. Strains were as follows: WT (SKY084-A), ∆*pep4* (SKY100-A), ∆*npr2* (SKY091-A), ∆*gtr1* (SKY244-A), ∆*npr2*∆*gtr1* (SKY245-A), ∆*ego1* (SKY129), ∆*npr2*∆*ego1* (YKY145), ∆*ego2* (YKY147), ∆*npr2*∆*ego2* (YKY146). (D) WT (SKY084-A), ∆*pep4* (SKY100-A), ∆*ego1* (SKY129), and ∆*ego2* (YKY147) cells harboring pRS316 or pSK205 (pRS316/pGal1-GST-Gtr1) were grown in SCGal medium until log phase and starved for 4 h in SD-N medium. Lysates were subjected to ALP assay.](382fig3){#F3}

The *∆ego1* and *∆ego3* mutants were defective in recovery from the growth arrest caused by rapamycin treatment ([@B8]; [Figure 3A](#F3){ref-type="fig"}). However, the growth of ∆*ego2* cells recovered as efficiently as that of WT cells ([Figure 3A](#F3){ref-type="fig"}). In addition, recovery from rapamycin-induced growth arrest was apparent in ∆*ego2*∆*npr2* cells, in contrast to ∆*ego1*∆*npr2* or ∆*ego3*∆*npr2* cells, supporting the idea that some Gtr1 function (and Gtr1-dependent TORC1 activation) persists in ∆*ego2* cells.

Next we examined the phosphorylation of Sch9, the substrate of TORC1 kinase, in ∆*ego2* cells. Immunoblotting after 2-nitro-5-thiocyanatobenzoic acid (NTCB) treatment to enhance the phosphorylation-dependent mobility shift revealed dephosphorylation of Sch9 upon rapamycin treatment or starvation ([@B53]). As reported previously, even under nutrient-rich conditions without rapamycin treatment, partial dephosphorylation was observed in ∆*gtr1* and ∆*ego1* cells relative to WT cells ([Figure 3B](#F3){ref-type="fig"}; [@B5]). By contrast, in ∆*ego2* cells, such significant dephosphorylation was not evident ([Figure 3B](#F3){ref-type="fig"}). We also examined Gtr1-dependent TORC1 activation by monitoring autophagy using an alkaline phosphatase (ALP) assay ([@B32]; [@B33]; [@B31]). In ∆*npr2* cells, even under nitrogen starvation, which induces autophagy through TORC1 inactivation in WT cells, autophagy was not induced ([Figure 3C](#F3){ref-type="fig"}; [@B24]). Accordingly, in the absence of Gtr1, TORC1 could not be activated in ∆*npr2* cells, and autophagy was induced normally by nitrogen starvation ([Figure 3C](#F3){ref-type="fig"}; [@B24]). Deletion of *EGO1* in ∆*npr2* cells had the same effect as the *GTR1* deletion, reflecting complete loss of Gtr1 function ([Figure 3C](#F3){ref-type="fig"}). However, deletion of *EGO2* in ∆*npr2* cells resulted in only partial induction of autophagy ([Figure 3C](#F3){ref-type="fig"}). Overproduction of the Gtr1-GTP mutant failed to suppress autophagy in ∆*ego1* cells but achieved partial suppression in ∆*ego2* cells ([Figure 3D](#F3){ref-type="fig"}). Taken together, these data indicate that Gtr1-dependent TORC1 activation was only partially defective in ∆*ego2* cells.

On the other hand, a mutant in Ynr034w-a/Ego4, another candidate Ego subunit ([@B26]; [@B39]), was not more sensitive to rapamycin than WT cells, and the ∆*ego4*∆*ego2* double mutant did not exhibit higher rapamycin sensitivity than the ∆*ego2* single mutant ([Figure 3A](#F3){ref-type="fig"}). Furthermore, we detected no two-hybrid interactions between Ego4 and Ego1, Ego3, or Ego2 (Supplemental Figure S1A, top), and neither C-terminally nor N-terminally GFP-tagged Ego4 was localized on the vacuole (Supplemental Figure S1B; unpublished data). These data suggest that Ego4 is not a subunit of Ego.

Ego2 is partially involved in anchoring Gtr complex on vacuole
--------------------------------------------------------------

Ego1 forms a complex with Gtr1 and Gtr2 ([@B10]), and we showed that Ego1-GFP colocalized with Gtr1-3xmCherry ([Figure 4A](#F4){ref-type="fig"}). Consistent with the foregoing model, in which Ego2 is a subunit of Ego, Ego2-GFP also colocalized with Gtr1-3xmCherry ([Figure 4A](#F4){ref-type="fig"}). We previously demonstrated that GFP-Tor1, replacing the endogenous *TOR1* gene and driven by its own promoter, complemented Tor1 function ([@B24]). Here we showed that Ego3-3xmCherry colocalized with GFP-Tor1 ([Figure 4B](#F4){ref-type="fig"}). We also determined the localization of another TORC1 subunit, Tco89 ([@B40]). N-terminally GFP-tagged Tco89 driven by its own promoter complemented the protein's native function, as determined by rapamycin-sensitivity assay (Supplemental Figure S3A). Like GFP-Tor1, GFP-Tco89 colocalized with Ego3-3xmCherry (Supplemental Figure S3B), indicating that these signals mostly represent the localization of TORC1. Therefore TORC1 proteins colocalize on the vacuole and the puncta with Ego1/2/3 Gtr1.

![The ∆*ego2* mutant exhibits a partial defect in vacuolar localization of Gtr1. (A, B) Diploid cells expressing Ego2-GFP and Gtr1-3xmCherry (YKY034-A; A) or GFP-Tor1 and Ego3-3xmCherry (YKY118-A; B). (C, D) Wild-type and mutant strains expressing Gtr1-GFP or Gtr2-GFP were stained with FM4-64. (C) WT (SKY112-A), ∆*gtr2* (SKY249-A), ∆*ego1* (SKY250-A), ∆*ego3* (SKY113-A), ∆*ego2* (SKY337-A). (D) WT (SKY259-A), ∆*gtr1* (SKY260-A), ∆*ego1* (SKY261-A), ∆*ego3* (SKY323-A), ∆*ego2* (SKY338-A). Bar, 5 μm.](382fig4){#F4}

In ∆*ego1* and ∆*ego3* mutants, localization of Gtr GTPases on the vacuole is lost ([Figure 4, C and D](#F4){ref-type="fig"}; [@B8]). By contrast, although vacuolar localization of Gtr1 was also significantly reduced in the ∆*ego2* mutant, a limited amount of Gtr1-GFP signal remained on the vacuole ([Figure 4C](#F4){ref-type="fig"}). This remaining Gtr1 may explain the partial Gtr1-dependent TORC1 activity in the ∆*ego2* mutant described in the preceding section.

Gtr1 is associated with Ego1 and Ego2 via C-terminal Roadblock domain
---------------------------------------------------------------------

As previously reported, an interaction between Gtr1 and Ego1 was observed by two-hybrid analysis ([Figure 5A](#F5){ref-type="fig"} and Supplemental Figure S1A, bottom; [@B11]; [@B5]; [@B45]). In addition, we observed a weak interaction between Gtr1 and Ego2 in both the AD and BD combinations ([Figure 5A](#F5){ref-type="fig"}). The Gtr1 protein consists of an N-terminal GTPase domain (G domain) and a C-terminal Roadblock domain ([@B12]; [@B17]), and we separately tested the interactions of both domains. We observed a weak interaction between Ego2 and the Roadblock domain ([Figure 5B](#F5){ref-type="fig"}) but no significant interaction between Ego2 and the G domain, even if it takes GTP-bound form ([Figure 5B](#F5){ref-type="fig"}). Similarly, Ego1 interacted with the Roadblock domain but not the G domain of Gtr1 and Ego1 ([Figure 5B](#F5){ref-type="fig"}). Thus Ego2 and Ego1 both interact with the C-terminal Roadblock domain of Gtr1. This is consistent with the idea that Gtr1 can be anchored to Ego1 even in the absence of Ego2 but that Ego2 strengthens the interaction.

![Ego1 and Ego2 interact with the Gtr1 Roadblock domain. (A) PJ69-4A cells harboring the indicated plasmids (pGAD-C1 and pGBD-C1, and pYKY009, 012, 013, pSK132, or 147) were grown on --His and +His plates for 6 d. (B) PJ69-4A harboring the indicated plasmids (Gtr1 G domain \[WT: pSK359; Q65L: pSK360; S20L: pSK361\] and Gtr1 Roadblock domain \[pSK362\], Ego1 \[pYKY024\], and Ego2 \[pYKY026\]) were grown on SD medium with or without histidine.](382fig5){#F5}

Gtr1 nucleotide-loading state affects localization of Ego/Gtr/Tor1
------------------------------------------------------------------

Next we focused on the observation that these proteins colocalized on perivacuolar puncta. Vph1, a subunit of V-ATPase and a general vacuolar membrane marker protein ([@B56]), did not show such frequent puncta pattern (as the fusion Vph1-mCherry), indicating that such localization is not a general phenomenon of vacuolar membrane proteins ([Figure 6D](#F6){ref-type="fig"}). The puncta did not exhibit significant overlap with other vacuolar membrane--associating puncta, such as the preautophagosomal structure (indicated by the marker ApeI) or late endosome (indicated by the marker Snf7; [@B2]; [@B50]; [Figure 6D](#F6){ref-type="fig"}). We also detected GFP-Sch9, a substrate of TORC1. As reported, GFP-Sch9 was enriched on the vacuolar membrane, but no obvious puncta similar to Ego were observed ([Figure 6E](#F6){ref-type="fig"}; [@B53]; [@B19]). However, almost half of the puncta (45%) were localized at sites positive for Nup49-mCherry, a nuclear envelope marker ([@B48]; [Figure 6D](#F6){ref-type="fig"}). The nuclear--vacuolar junction marker Vac8 also exhibited significant overlap (43%; [@B35]; [Figure 6D](#F6){ref-type="fig"}), implying that the puncta tend to be organized at nuclear--vacuolar junctions.

![Localization of Ego proteins in ∆*gtr* mutants and the relationship with the other markers. (A--C) Wild-type, ∆*gtr1*, and ∆*gtr2* cells expressing (A) Ego1-GFP, (B) Ego3-GFP, and (C) Ego2-GFP. The mean and standard deviation of percentages of cells having GFP puncta from three independent experiments (200--300 cells each) are shown. Strains were as follows: Ego1-GFP (WT: SKY108-A; ∆*gtr1*: SKY262-A; ∆*gtr2*: SKY263-A), Ego3-GFP (WT: SKY114-A; ∆*gtr1*: SKY327-A; ∆*gtr2*: SKY361-A), and Ego2-GFP (WT: SKY331-A; ∆*gtr1*: SKY351-A; *∆gtr2*: SKY352-A). (D) Cells expressing GFP-Tor1 and C-terminally mCherry-tagged Snf7 (SKY236-A), Vph1 (SKY461-A), ApeI (SKY395-A), Nup49 (SKY374-A), or Vac8 (SKY451-A). Arrowheads indicate GFP-Tor1 punctate structure adjacent to Nup49-labeled nuclear envelope, and GFP-Tor1 dots colocalized with the Vac8 perivacuolar dot structure. Bar, 5 μm. (E) Cells expressing pNop1-GFP-Sch9 and Ego3-3xmCherry (SKY519). Bar, 5 μm.](382fig6){#F6}

This punctate localization of Ego1, Ego3, and Ego2 was mostly absent in the *GTR1* and *GTR2* deletion mutants, whereas vacuolar membrane localization persisted ([Figure 6, A--C](#F6){ref-type="fig"}). Thus the Gtr proteins play critical roles in punctate localization. Lack of punctate localization of Ego1-GFP in the ∆*ego3* and ∆*ego2* mutants could be attributed to loss of Gtr1/2 localization in these mutants ([Figure 1D](#F1){ref-type="fig"}). Previously, we reported that the GTP/GDP form of Gtr1 affects GFP-Tor1 localization ([@B24]). When Gtr1 is in the GTP-bound form, GFP-Tor1 preferentially localizes on the vacuole membrane ([@B24]). We also investigated whether the punctate localization of GFP-Tor1 was affected by the nucleotide-loading state of Gtr1. The Gtr1 Q65L mutant (a mimic of the GTP-bound state; [@B10]) dramatically decreased the punctate localization of GFP-Tor1, whereas the Gtr1 S20L mutant (a mimic of the GDP-bound state) increased the number of puncta ([Figure 7A](#F7){ref-type="fig"}). We also confirmed that vacuolar localization of GFP-Tco89, like that of GFP-Tor1, was elevated in cells expressing Gtr1-GTP Gtr2-GDP (Supplemental Figure S3C; [@B24]).

![Tor1 and Ego protein localization in Gtr1 nucleotide-loading-state mutant. (A) GFP-Tor1 ∆*gtr1* (SKY278-A) cells harboring pRS316 or Gtr1 (WT: pSK114; Q65L\[GTP\]: pSK116; and S20L\[GDP\]: pSK115 mutant). Bar, 5 μm. (B) ∆*gtr1* cells (NKY004) harboring single-copy plasmid expressing Gtr1-GFP (WT: pSK274; Q65L\[GTP\]: pSK277; and S20L\[GDP\]: pSK286 mutant) were subjected to microscopy. (C--E) ∆*gtr1* cells expressing (C) Ego1-GFP (SKY262-A), (D) Ego3-GFP (SKY327-A), or (E) Ego2-GFP (SKY351-A) and harboring a plasmid encoding Gtr1 (WT: pSK114; Q65L\[GTP\]: pSK116; and S20L\[GDP\]: pSK115 mutant). Bar, 5 μm. The mean and standard deviation of percentages of cells having GFP puncta from three independent experiments (200--300 cells each) are shown.](382fig7){#F7}

The GFP-labeled GTP-bound Gtr1 mutant itself also mostly localized on the vacuolar membrane and barely localized at puncta ([Figure 7B](#F7){ref-type="fig"}). By contrast, the GDP-bound Gtr1 mutant was exclusively found on puncta ([Figure 7B](#F7){ref-type="fig"}). Although the GDP-bound Gtr1 mutant was unstable relative to the WT protein (Supplemental Figure S2A), the intensities of the punctate signals of the mutant protein did not decrease ([Figure 7B](#F7){ref-type="fig"}).

Localization of Ego subunits was also affected by the nucleotide-loading state of Gtr1. In GTP-bound Gtr1 mutant cells, Ego1, Ego3, and Ego2 were exclusively localized on the vacuolar membrane, and the punctate signals were mostly absent ([Figure 7, C--E](#F7){ref-type="fig"}). On the contrary, the number of cells containing Ego puncta were elevated in GDP-bound Gtr1 mutant cells, in which the signals on the vacuolar membrane were greatly reduced ([Figure 7, C--E](#F7){ref-type="fig"}), although the expression levels of Ego1/3/4-GFP were not affected in these mutants (Supplemental Figure S2, B--D). Taking the results together, we concluded that the Gtr1 nucleotide-bound state affects localization of Ego/Gtr/TORC1.

Gtr2 actively localizes TORC1 on perivacuolar foci
--------------------------------------------------

We previously reported that GFP-Tor1 is localized primarily on puncta in the ∆*gtr1*∆*gtr2* double mutant ([@B24]), suggesting that puncta are the default destination of TORC1 in the absence of Gtr proteins. Gtr1 lacking only the G domain (Gtr1∆G) was able to localize on the vacuolar membrane ([Figure 8A](#F8){ref-type="fig"}), but GFP-Tor1 was mostly mislocalized on puncta ([Figure 8C](#F8){ref-type="fig"}), supporting the suggestion that the Gtr1 G domain is required for TORC1 vacuolar localization. Consistently, Gtr1∆G was not able to activate TORC1, as determined by the rapamycin-sensitivity assay ([Figure 8E](#F8){ref-type="fig"}).

![Gtr2 G domain is required for Gtr1-dependent TORC1 activation. (A, B) WT, ∆*gtr1*, and ∆*gtr2* (KNY 004, KNY 005) harboring (A) pRS316/Gtr1∆G-GFP and (B) pRS316/Gtr2∆G-GFP. (C, D) GFP-Tor1 in ∆*gtr1* or ∆*gtr*2 (SKY278-A, SKY279-A) harboring Gtr1,2-WT (pSK114, pSK100) or Gtr1,2∆G (pSK291, pSK293). Percentage of cells in which GFP-Tor1 is detected over the vacuolar membrane is shown for each image. The average of three independent experiments (200--300 cells each) is shown. (E) ∆*gtr1* or ∆*gtr2* (EUROSCARF) harboring empty vector (pRS316), pSK114, pSK291, pSK100, or pSK293 was serially 10-fold diluted and spotted on YPD plates with or without 0.2 μg/ml rapamycin and grown at 30°C for 3 d. (F) WT (SKY084-A) or ∆*pep4* (SKY100-A) harboring empty vector and ∆*gtr1*∆*gtr2* harboring empty vector, Gtr1-GTP Gtr2-GDP (pSK129), or Gtr1-GTP Gtr2∆G (pSK345), cultured logarithmically in SCD or starved for 4 h in SD-N medium, were subjected to ALP assay.](382fig8){#F8}

When Gtr2 is deleted, Gtr1 cannot be localized on the vacuole, suggesting that Gtr1/Gtr2 heterodimer formation stabilizes the protein's normal localization ([@B24]). We found that Gtr2 lacking only the G domain (Gtr2∆G) could be localized on the vacuolar membrane in a Gtr1-dependent manner ([Figure 8B](#F8){ref-type="fig"}) and to maintain Gtr1-GFP localization on the vacuole ([Figure 9A](#F9){ref-type="fig"}). However, GFP-Tor1 was mislocalized on puncta in the Gtr2∆G mutant ([Figure 8D](#F8){ref-type="fig"}). Therefore Gtr1-dependent localization of TORC1 is defective in Gtr2 lacking the G domain, even though Gtr1 is localized on the vacuole. Furthermore, Gtr2∆G did not complement the rapamycin sensitivity of *∆gtr2* cells ([Figure 8E](#F8){ref-type="fig"}). Autophagy was suppressed by expression of Gtr1-GTP in Gtr2-GDP cells but not in the Gtr2∆G mutant ([Figure 8F](#F8){ref-type="fig"}). Therefore Gtr1-dependent activation of TORC1 is also defective in Gtr2-expressing cells that lack the G domain.

![Gtr2 affects Gtr1 and Tor1 perivacuolar localization. (A, B) Localization of Gtr1-GFP in various Gtr2 mutants, determined by microscopy. Gtr1-GFP WT (SKY112-A) and ∆*gtr2* (SKY249-A), harboring a plasmid expressing Gtr2 WT (pSK100) and Gtr2-∆G (pSK293; A), and a Gtr2-GTP mutant (pSK93) and Gtr2-GDP mutant (pSK92; B).](382fig9){#F9}

When the Gtr2 G domain was deleted, localization on Gtr1-GFP puncta was still mostly absent, indicating that the Gtr2 G domain is also important for formation of Gtr1-GFP puncta ([Figure 9A](#F9){ref-type="fig"}), although both the GTP and GDP forms of Gtr2 mutants maintain GFP-Gtr1 puncta formation ([Figure 9B](#F9){ref-type="fig"}). Therefore the Gtr2 G domain determines Gtr1 localization independent of its nucleotide-bound form.

We next investigated whether Gtr2 participates actively in TORC1 localization on puncta. We reported previously that Gtr2 binds directly to the TORC1 subunit Kog1, and this interaction is involved in suppressing TORC1 activity when Gtr1 is in the GDP-bound form ([@B24]). A Gtr2 allele with a point mutation at the probable Kog1-binding surface (E62K) loses its Kog1-binding capacity and TORC1 suppression activity ([@B24]). However, even in the ∆*gtr1*∆*gtr2* double mutant expressing Gtr1 (GDP) Gtr2 (E62K), GFP-Tor1 formed puncta to approximately the same degree as in the Gtr1 (GDP) mutant (Supplemental Figure S3D). However, as just detailed, GFP-Tor1 is also localized on puncta in the absence of Gtr proteins, and we were not able to determine whether loss of TORC1 association in the Gtr1 (GDP) Gtr2 (E62K) mutant leads to GFP-Tor1 puncta mislocalization.

To investigate the foregoing possibility, we artificially targeted GFP-Tor1 to the vacuolar membrane by achieving expression of GFP-binding protein (GBP; [@B25]) on the vacuolar membrane. To achieve this, we linked GBP to the cytoplasmic region of the vacuolar-resident, single-transmembrane protein alkaline phosphatase (Pho8), which lacks the catalytic center (i.e., amino acids 120--128 are absent). In a control experiment, this GBP-Pho8 chimeric protein was successfully shown to target GFP-Atg8 protein (which otherwise does not localize on the vacuole; [@B51]) on the vacuolar membrane (Supplemental Figure S4, A and B). Similarly, expression of GBP-Pho8 recovered vacuolar membrane localization of GFP-Tor1 in ∆*gtr1*∆*gtr2* cells, so that the percentage of such cells (35.4%) is similar to the levels of WT Gtr1/2 expression (35.9%; Supplemental Figure S4C). In particular, quantitative line-plot analysis showed that Gtr1-GDP Gtr2-GTP cells expressing GBP-Pho8 had a weaker GFP-Tor1 signal on the vacuolar membrane than ∆*gtr1*∆*gtr2* cells ([Figure 10, A and B](#F10){ref-type="fig"}). On the other hand, both the Gtr2∆G and Gtr2 (E62K) mutants expressing GBP-Pho8 had GFP-Tor1 signal intensities on the vacuolar membrane similar to that of the ∆*gtr1*∆*gtr2* mutant ([Figure 10, A and B](#F10){ref-type="fig"}). These findings show that the Gtr2 G domain actively facilitates perivacuolar foci localization of TORC1 by means of direct binding to Kog1.

![Gtr2 actively participate in the formation of the puncta of TORC1. (A) GFP-Tor1 ∆*gtr1*∆*gtr2* (SKY50-A) cells harboring both pRS314 (empty or pRS314/pADH1-GBP-Pho8^∆120--128^ \[pSK413\]) and pRS316 (empty, pRS316/Gtr1-GDP Gtr2-GTP \[pSK127\], pRS316/ Gtr1-GDP Gtr2-E62K \[pSK256\], or pRS316/Gtr1-GDP Gtr2-∆G \[pSK344\]) series vectors were stained with FM4-64. Percentages of cells showing GFP-Tor1 localization on vacuolar membrane are shown for each image; average of three independent experiments (200--250 cells each. Right, signal intensities of GFP-Tor1 and FM4-64 along the indicated lines measured by ImageJ software (see *Materials and Methods*). (B) Signal intensities of GFP-Tor1 on the vacuolar membrane measured in A. Average and SD of the intensities from 40 points. Pixel size, 0.07 μm. \**p* \< 0.01 (*t* test).](382fig10){#F10}

Taken together, these data show that the localization of TORC1/Gtr/Ego on puncta is regulated by the nucleotide-loading state of Gtr1 and Gtr2. It is therefore expected that, when Gtr1 activates and Gtr2 inactivates TORC1, the localization of TORC1/Gtr/Ego will be shifted dynamically between the vacuolar membrane and the puncta.

DISCUSSION
==========

Our findings in this study, together with those of a recent report ([@B39]), show that Ycr075w-a is a novel subunit of the yeast Ego; accordingly, it has been named Ego2. Thus yeast Ego consists of at least four subunits: one molecule of Ego1, two of Ego3, and one of Ego2. By contrast, mammalian Ragulator consists of five subunits (p18/Lamtor1, p14/Lamtor2, MP1/Lamtor3, C7orf59/Lamtor4, and HBXIP/Lamtor5). Therefore it is reasonable to speculate that yeast Ego contains one more subunit; this notion is supported by the observation that most Roadblock proteins, including Ego2, exhibit a dimeric organization ([@B26]). One potential additional subunit is Ynr034w-a/*ego4*, considered as a candidate based on its secondary structure ([@B26]), and another possibility is that two molecules of Ego2 proteins are present (as in the case of Ego3; [@B55]). Despite several attempts (Supplemental Figure S1A; unpublished data), no positive data supporting these hypotheses are available. [@B39]) reported a crystal structure of Ego2 in complex with Ego3. In any case, identification of Ego2 has prompted us to discuss the overall structural relationship between yeast Ego and mammalian Ragulator.

Unexpectedly, despite the clear association of Ego2 with Ego ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}), the ∆*ego2* mutant caused only a partial defect in Gtr1-dependent TORC1 activation, in contrast to the phenotypes of the ∆*ego1* and ∆*ego3* mutants ([Figure 3](#F3){ref-type="fig"}); this fact was not mentioned in [@B39]). The difference between ∆*ego1*/∆ego*3* and ∆*ego2* could be attributed to the different efficiencies of Gtr1 association with the vacuole in each mutant: in ∆*ego2*, the Gtr1-GFP signal on the vacuole was dramatically reduced but persisted to some extent, whereas in ∆*ego1*, the signal was completely eliminated ([Figure 4](#F4){ref-type="fig"}). Because Gtr1 directly binds to Ego1 via its Roadblock domain ([Figure 5B](#F5){ref-type="fig"}), at least a small fraction of Gtr1 can be anchored to the vacuole via Ego1 even in the absence of Ego2, and this might be sufficient for partial TORC1 activation. Ego2 may facilitate this binding via direct interaction with Gtr1 ([Figure 5A](#F5){ref-type="fig"}) and/or stabilization of the association between Ego3 and Ego1 ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). Meanwhile, it is intriguing that the *ego3* mutant exhibited the same degree of rapamycin sensitivity as the *ego1* mutant ([Figure 3A](#F3){ref-type="fig"}). Ego3 seems to play a more critical role in Gtr1-dependent TORC1 activation than Ego2 ([Figure 3](#F3){ref-type="fig"}), although no direct interaction between Ego3 and Gtr1 could be detected by two-hybrid analysis (Supplemental Figure S1A). However, the ∆*ego2* mutant also had a defect in Ego3 localization ([Figure 1C](#F1){ref-type="fig"}). These observations might be reconciled if a very low level (not detectable using our microscope system) of Ego3 remains on the vacuole in the ∆*ego2* mutant. This possibility is consistent with the observation that Ego2-GFP is slightly detectable on the vacuole even in ∆*ego3* mutant cells ([Figure 1B](#F1){ref-type="fig"}). In any case, Ego3 seems to exert a greater effect on Gtr1 than does Ego2. In mammals, Ragulator has been proposed to play a role not only as a scaffold but also as a guanine nucleotide exchange factor (GEF) for RagA/B, which corresponds to Gtr1 ([@B4]). It is reasonable to hypothesize that Ego also possesses such a function, and these observations support further investigations of that possibility. [@B39]), however, showed that artificial targeting of Gtr1/Gtr2 in ∆*ego1*∆*ego2*∆*ego3* cells can activate TORC1, indicating that Gtr1 can bypass all functions of Ego other than its role as a scaffold. Vam6/Vps39 may serve as the GEF for Gtr1, at least in yeast ([@B5]).

By analyzing the detailed localization of Ego2, we showed for the first time that Ego1, 3, and 2, Gtr1 and 2, and TORC1 are colocalized on the vacuole and its associated puncta ([Figure 4, A and B](#F4){ref-type="fig"}). In particular, puncta localization should be of interest because the accumulation at puncta seems to be an active process directed by Gtr1 and nucleotide-loading status ([Figure 7](#F7){ref-type="fig"}). Because Ego1 is anchored to the vacuolar membrane via its N-terminal lipid modification ([Figure 1E](#F1){ref-type="fig"}), the puncta are likely to represent the accumulation of these proteins on the vacuolar surface rather than a structure that is detached from the vacuole. This accumulation tends to form at nuclear--vacuolar junctions ([Figure 6D](#F6){ref-type="fig"}), possibly because the proteins maybe trapped by a physical barrier generated by contact between two bulky organelles. Recent work showed that the I-BAR protein Ivy1, which plays a role in vacuolar morphology, is also colocalized with Gtr and Ego on the vacuole and puncta, and it also colocalizes with Ypt7 ([@B34]). Therefore these puncta may be important for vacuolar morphology. The GTP form of Gtr1 seems to be necessary for localization of TORC1 on the vacuolar membrane; without it, TORC1 tends to accumulate at the puncta ([Figure 8C](#F8){ref-type="fig"} and Supplemental Figure S3C; [@B24]), suggesting that the puncta are the default destination. However, our results argue against such a simple interpretation. The efficiency of GFP-Tor1 targeting to the vacuolar membrane, using an artificial method based on the affinity between GFP and GBP, was higher in a mutant lacking Gtr1 and Gtr2 than in the Gtr1-GDP and Gtr2-GTP mutants ([Figure 10](#F10){ref-type="fig"}). This increase was also observed in a mutant lacking the Gtr2 G domain or in cells expressing Gtr2 lacking the ability to bind TORC1 (E62K; [Figure 10](#F10){ref-type="fig"}). These data indicate that in combination with default puncta formation, Gtr2-GTP also actively participates in recruiting TORC1 to the puncta. This is in agreement with our previous proposal that Gtr2 functions directly in the inactivation of TORC1 ([@B24]). Thus Gtr1 and Gtr2 play a tug of war, pulling TORC1 between the vacuolar membrane and puncta according to their nucleotide-loading status.

Activation of TORC1 by the GTP form of Gtr1 promotes vacuolar membrane localization ([Figure 7A](#F7){ref-type="fig"}). Moreover, in contrast to ∆*ego1* and ∆*ego3*, in the ∆*ego2* mutant, Gtr1 was still partially localized to the vacuolar membrane, and partial Gtr1-dependent TORC1 activity persisted ([Figures 3](#F3){ref-type="fig"} and [4C](#F4){ref-type="fig"}). In the mammalian system, mTORC1 is activated by recruitment to the lysosome via the Rag complex and resulting encounter with the activator Rheb GTPase ([@B41]). However, in the yeast system, it is unclear how activation is achieved and whether the Rheb homologue is involved ([@B52]). It is an open question whether this dynamic relocation is associated with the regulation of TORC1 activity. If a hypothetical TORC1-activating molecule (corresponding to mammalian Rheb) is scattered over the vacuolar membrane, this relocation could lead to the regulation of TORC1 activity. Alternatively, a more plausible role for this dynamic relocation is that it would make TORC1 protein kinase more easily accessible to its substrates by dispersing it throughout the vacuolar membrane rather than allowing it to remain concentrated on the puncta. For example, Sch9, a TORC1 substrate protein, is enriched on the vacuolar membrane ([Figure 6E](#F6){ref-type="fig"}; [@B53]; [@B19]). Another soluble substrate, Atg13, is localized on the vacuole-associated preautophagosomal structure (PAS) when it is dephosphorylated under starvation conditions ([@B51]; [@B22]). On addition of nutrients, Atg13 is rapidly phosphorylated by TORC1 ([@B20]). Because the PAS is distinct from the Gtr/Ego/Tor1 puncta, although it is associated with the vacuolar membrane ([Figure 6D](#F6){ref-type="fig"}), TORC1 would be unable to encounter Atg13 until it is disseminated throughout the vacuolar membrane. However, one observation that makes interpretation more difficult is that simply shifting cells from nutrient-rich to nitrogen-starvation conditions did not dramatically induce such relocation ([@B24]). This can be reconciled by the additional observation that even in the absence of Gtr1, autophagy is induced mostly normally ([@B24]), implying the existence of a Gtr1-independent TORC1 activation pathway ([@B49]). In addition, artificial targeting of Tor1 onto the vacuolar membrane could not fulfill the function of Gtr1/Gtr2, at least in the experimental system we used ([Figure 10, A and B](#F10){ref-type="fig"}, and Supplemental Figure S4D). Future studies should give a clearer view of the physiological relevance of this dramatic relocation.

By identifying Ego2 as an additional subunit of yeast Ego, this study provides insight into the detailed mechanisms underlying the dynamics of the Ego/Gtr/TORC1 proteins. Our findings should help to fundamentally elucidate the regulation of TORC1 by nutrient availability.

MATERIALS AND METHODS
=====================

Yeast strains, media, and plasmid construction
----------------------------------------------

Yeast strains used in this study, most of them BY4741/4742 background ([@B6]), are listed in Supplemental Table S1. Yeast cells were grown in YPD (1% yeast extract \[BD Biosciences, San Jose, CA\]; 2% peptone \[BD Biosciences; 2% glucose \[Wako, Osaka, Japan\]) or SCD (0.17% yeast nitrogen base without amino acids and ammonium sulfate \[BD Biosciences\], 0.5% (NH~4~)~2~SO~4~ \[Nacalai Tesque, Kyoto, Japan\], 0.5% casamino acid \[BD Biosciences\], 2% glucose), or SCG (0.17% yeast nitrogen base without amino acids and ammonium sulfate \[BD Biosciences\], 0.5% (NH~4~)~2~SO~4~ \[Nacalai Tesque\], 0.5% casamino acid \[BD Biosciences\], 2% galactose). Strain construction, gene deletion, and chromosomal epitope tagging were performed as previously reported ([@B29]; [@B16]; [@B23]; [@B30]). For two-hybrid analysis, to replace the *LEU2* marker of pGBD-C1 with *TRP1*, a fragment containing *TRP1* was PCR amplified from pRS314, digested with *Pvu*II and *Cla*I, and cloned into pGBD-C1, which was digested with *Pvu*II and *Cla*I to remove the region containing *LEU2*. The resultant plasmid was named pSK272. *GTR1* (full-length, G domain \[amino acids 1--184\], Roadblock \[RD\] domain \[amino acids 185-310\]), *EGO1*, *EGO3*, *EGO2*, and *YNR034W-A* were PCR amplified from genomic DNA and cloned into pGAD-C1, pGBD-C1, and pSK272 ([@B15]; Supplemental Table S2). *GTR1-GFP* and *EGO1-GFP* fragments, including their promoters (818 and 822 base pairs) and terminators (583 and 516 base pairs) were amplified from the respective genomically tagged strains (Supplemental Table S1), digested with *Sac*I/*Xba*I and *Sac*I/*Kpn*I, and cloned into pRS316 ([@B47]). Point mutations (*GTR1* \[S20L, Q65L\], *EGO1* \[G2A\]) were introduced by two-step PCR to generate pSK277, pSK286, and pSK385, respectively. The proGal1-GST-Gtr1-termGtr1 cassette was amplified from a genomically tagged yeast strain ([@B29]) and cloned into the *Xba*I/*Sac*I sites of pRS316, and then Q65L point mutation was introduced to generate pSK196. The C-terminal RD domains of Gtr1 and Gtr2 (amino acids 185--311 and 185--341, respectively), under the control of their own promoters (1000 base pairs) and terminators (500 base pairs), were digested with *Sac*I/*Xba*I or *Bam*HI/*Xho*I and cloned into pRS316 to generate pSK291 and pSK293, respectively. The RD domains of Gtr1 and Gtr2 fused with GFP, connected to their own promoters and terminators by PCR, were digested with *Sac*I/*Xba*I or *Kpn*I/*Xho*I and cloned into pRS316 to generate pSK290 and pSK294, respectively. GBP-Pho8 was constructed as follows: 1000 base pairs of proADH1 was amplified by PCR and cloned into the *Bam*HI/*Eco*RI sites of pRS314 to generate pSK409. GBP amplified from pGEX-6P/GST-GFP-nanobody ([@B21]) and Pho8 open reading frame lacking its alkaline phosphatase activation center (amino acids 120--128) were fused by PCR and cloned into the *Eco*RI/*Kpn*I sites of pSK409 to generate pSK413.

Microscopy
----------

Cells grown in SCD were collected with centrifugation (600 × *g*, 2 min) and subjected to microscopy. For FM4-64 staining, cells were pelleted and resuspended in 100 μl of culture medium containing 1 μl of 1.64 mM FM4-64, incubated for 30 min, washed twice with 1 ml SCD medium, incubated for 1 h, and then subjected to microscopy. Yeast cells were observed on a Leica AF6500 fluorescence imaging system (Leica Microsystems) mounted on a DIM6000 B microscope (HCX PL APO 63.6/1.40--0.60 oil-immersion objective lens, xenon lamp; Leica Microsystems, Wetzlar, Germany) under the control of the LAS-AF software (Leica Microsystems). Line-plot analysis of GFP signal intensities was conducted with ImageJ software (National Institutes of Health, Bethesda, MD) by the following procedure: designated lines were set across single vacuole, avoiding perivacuolar puncta. The intensity of GFP at a pixel corresponding to FM4-64 peak signal intensities was subtracted from intensities of the background region over ≥10 pixels.

TAP pull-down assay
-------------------

TAP pull-down assays were performed as previously reported ([@B24]).

NTCB treatment for Sch9
-----------------------

NTCB treatments were performed as previously reported, with slight modifications ([@B53]). Briefly, 10 OD units of cells were treated with 6% trichloroacetic acid for 10 min on ice, washed twice with ice-cold acetone, and dried using a SpeedVac. The pellets were redissolved in 100 μl of urea buffer (50 mM Tris-Cl, pH 7.5, 5 mM EDTA, 6 M urea, 1% SDS, 1 mM phenylmethylsulfonyl fluoride, 1× Phos-Stop \[Roche, Basel, Switzerland\]) and vortexed with the same volume of 0.6-mm-diameter zirconia beads (Biomedical Science, Tokyo, Japan) for 10 min at 4°C. After centrifugation at 20,000 × g for 10 min at 4°C, the lysate were mixed with 30 μl of 1 M 2-(cyclohexylamino)ethanesulfonic acid (pH 10.5) and 20 μl of 7.5 M NTCB and incubated overnight at room temperature. Each sample was mixed with 50 μl of 4× loading buffer (800 mM Tris-Cl, pH 6.8, 6% SDS, 400 mM dithiothreitol, 8 M urea, 0.04% bromophenol blue) and subjected to SDS--PAGE and Western blot analysis.

Antibodies
----------

Anti--protein A (P-3775; Sigma-Aldrich, St. Louis, MO), anti-GFP (11814460001; Roche), anti-PGK (459250; Thermo Fisher Scientific, Waltham, MA), and anti-hemagglutinin (HA; 16B12; Covance, Princeton, NJ) antibodies were used for Western blotting.

Yeast two-hybrid analysis
-------------------------

Yeast two-hybrid analysis was carried out as described previously ([@B15]; [@B24]). A final concentration of 3 mM 3-aminotriazole was added to SD plates lacking histidine and supplemented with amino acids ([@B46]).

ALP assays for autophagy measurement
------------------------------------

ALP assays for autophagy measurements were performed as previously reported ([@B24]).
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ALP

:   alkaline phosphatase

GBP

:   GFP-binding protein

NTCB

:   2-nitro-5-thiocyanatobenzoic acid

TAP

:   tandem affinity purification

TORC1

:   target of rapamycin complex 1

WT

:   wild type.
